Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
HeartBeat.bio logo — HeartBeat.bio develops 3D screening platform for heart failu...

HeartBeat.bio

HeartBeat.bio develops 3D screening platform for heart failure and cardiomyopathy using self-organizing Cardioids.

Founded 2021

General Information

Company Name HeartBeat.bio
Founded Year 2021
Social

Get notified when HeartBeat.bio moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About HeartBeat.bio

HeartBeat.bio is a Vienna-based startup founded in 2021, dedicated to revolutionizing cardiovascular drug discovery. The company’s 3D screening platform utilizes self-organizing Cardioids, which closely mimic human heart chambers. This breakthrough technology enables cost-effective, large-scale in-vitro analysis of clinical parameters related to heart failure and cardiomyopathy. With its innovative approach, HeartBeat.bio aims to transform the cardiovascular drug discovery landscape. Established on January 1, 2021, the company presents an exciting opportunity for venture capital investors seeking to support groundbreaking advancements in the healthcare industry.

Taxonomy: Cardioid-based screening platform, 3D screening technology, Heart failure, Cardiomyopathy, Drug discovery company, Vienna, Austria, Innovative technology, High-throughput analysis, Cardiac organoids, Clinical parameters, Cardiovascular diseases, Start-up, Investment opportunity

No funding data available for HeartBeat.bio yet.

Get notified when HeartBeat.bio raises funding

Latest News

View All
Austrian biotech HeartBeat.bio secures €4.5M for cardioid drug discovery platform — Tech
Austrian biotech HeartBeat.bio secures €4.5M for cardioid drug discovery platform
Tech Jan 23, 2024
Tensor Ventures launches €50M Fund: A boost for quantum, biotech, and climatetech startups — Tech
Tensor Ventures launches €50M Fund: A boost for quantum, biotech, and climatetech startups
Tech Oct 11, 2024
10 fast-growing Austrian startups to watch closely in 2025 — Eu-startups
10 fast-growing Austrian startups to watch closely in 2025
Eu-startups Nov 23, 2025

HeartBeat.bio Alternatives & Competitors

HeartBeat.bio vs
HeartBeat.bio AG
HeartBeat.bio AG Austria

REINVENTING CARDIAC DRUG DISCOVERY

Seed
22 employees
Biotechnology
HeartBeat.bio vs
StemoniX
StemoniX United States

Pre-plated, human iPSC-derived microOrgans for toxicology and drug discovery research

Convertible Note
1 employees
Biotechnology, Health Care
HeartBeat.bio vs
Metrion Biosciences
Metrion Biosciences United Kingdom

Specialist preclinical CRO

Series C
42 employees
Biotechnology, Health Care

FAQ About HeartBeat.bio

HeartBeat.bio develops 3D screening platform for heart failure and cardiomyopathy using self-organizing Cardioids.
HeartBeat.bio was founded in 2021.
Top alternatives and competitors to HeartBeat.bio include HeartBeat.bio AG, StemoniX, Metrion Biosciences, Domainex, BioTrove. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
HeartBeat.bio and HeartBeat.bio AG are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors HeartBeat.bio and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy